PIEB Compared With CEI on Breakthrough Pain in Nulliparous Women

Launched by HOLY FAMILY HOSPITAL, NAZARETH, ISRAEL · Jul 2, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how two different methods of providing pain relief during labor affect breakthrough pain in first-time mothers (nulliparous women). The study aims to see if a technique called programmed intermittent bolus epidural analgesia, which delivers pain relief medication in bursts every hour, is more effective than the standard continuous epidural infusion, where the medication is given steadily throughout labor.

To participate in this trial, women must be first-time mothers with a single baby in the head-down position, be in the early stages of labor (with less than 6 cm of cervical dilation), and have requested epidural pain relief due to significant pain. They will be randomly assigned to one of the two pain relief methods during their labor. It’s important to note that certain conditions, such as having a very large baby or specific health issues, would prevent someone from joining the study. Overall, participants can expect to help researchers learn more about effective pain management during labor, which could benefit future mothers.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Nulliparous women
• • Term pregnancy
• • Singleton
• • Vertex presentation
• • Latent phase (cervical dilatation \<6 cm)
• • Epidural analgesia request
• • Visual Analogue Scale score \> 40
• Exclusion Criteria:
• • Estimated fetal weight \> 4 kg
• • Intra uterine fetal death
• • Drug sensitivity
• • Anomalous fetus
• • Contraindication for epidural analgesia